Evommune Inc: RBC cuts target price to $30 from $50

RBC Capital has revised its price target for Evommune Inc (NYSE:EVMN), cutting it to $30 from $50, while maintaining an outperform rating. The updated target reflects a 29% upside from the current stock price of $24, as of June 29, 2026. The firm highlighted the company’s progress in inflammation and immunology, particularly with its lead agents ’756 and ’301, but noted increased caution ahead of key phase II data for chronic spontaneous urticaria.

Evommune has seen a 40% surge year-to-date, though some analysts suggest the stock may be overvalued relative to its fair value. The company recently raised $125 million through a private placement to support R&D efforts and reported positive top-line results from its Phase 2a trial for EVO301, an eczema drug targeting the interleukin-18 pathway. The drug demonstrated a 33% improvement in the Eczema Area and Severity Index at week 12.

Despite the lowered price target, RBC Capital and other analysts continue to express optimism about Evommune’s pipeline and potential for meaningful long-term revenue, particularly with multiple Phase 2 trial readouts expected in 2026.